Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis
Haruya Kawase, Yoshiyuki Bando, Kazuyuki Nishimura, et al.
Journal of Molecular and Cellular Cardiology (2016) Vol. 98, pp. 37-47
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
Christian Devaux, Jean‐Marc Rolain, Didier Raoult
Journal of Microbiology Immunology and Infection (2020) Vol. 53, Iss. 3, pp. 425-435
Open Access | Times Cited: 477
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
Circulation (2017) Vol. 136, Iss. 16, pp. 1548-1559
Closed Access | Times Cited: 205
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
Maria Mirabelli, Eusebio Chiefari, Luigi Puccio, et al.
International Journal of Environmental Research and Public Health (2020) Vol. 17, Iss. 10, pp. 3664-3664
Open Access | Times Cited: 57
DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
Jianqiang Zhang, Qiuyue Chen, Jixin Zhong, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 43
DPP4 as a Potential Candidate in Cardiovascular Disease
Siyu Chen, Kong Xiangquan, Ke-Fan Zhang, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 5457-5469
Open Access | Times Cited: 25
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)–Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1–Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway
Kosuke Okabe, Shouji Matsushima, Soichiro Ikeda, et al.
Hypertension (2020) Vol. 75, Iss. 4, pp. 991-1001
Open Access | Times Cited: 33
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
Juliana Isa Beraldo, Acaris Benetti, Flávio A. Borges-Júnior, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1940-1940
Open Access | Times Cited: 34
Epicardial fat and atrial fibrillation: the perils of atrial failure
Andrea Poggi, Bénédicte Gaborit, Thomas H. Schindler, et al.
EP Europace (2022) Vol. 24, Iss. 8, pp. 1201-1212
Closed Access | Times Cited: 18
Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system
Xifeng Yang, Yijie Qi, Jinxuan Hao, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Bidirectional relation between dipeptidyl peptidase 4 and angiotensin II type I receptor signaling
Flavia L. Martins, João Carlos Ribeiro-Silva, Ravi Nistala, et al.
AJP Cell Physiology (2024) Vol. 326, Iss. 4, pp. C1203-C1211
Closed Access | Times Cited: 3
The regulatory role of DPP4 in atherosclerotic disease
Lihua Duan, Xiaoquan Rao, Chang Xia, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 27
Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial
Luciana Neves Cosenso-Martin, Luiz Tadeu Giollo-Júnior, Letícia Aparecida Barufi Fernandes, et al.
Acta Diabetologica (2018) Vol. 55, Iss. 12, pp. 1237-1245
Closed Access | Times Cited: 22
Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
Satoru Kuriyama
Clinical and Experimental Nephrology (2018) Vol. 23, Iss. 3, pp. 304-312
Closed Access | Times Cited: 17
Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury
Zhen Zhang, Xiang Jin, Chunfeng Yang, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 109, pp. 468-474
Open Access | Times Cited: 16
Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu
Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, et al.
Life Sciences (2020) Vol. 256, pp. 117916-117916
Open Access | Times Cited: 12
Teneligliptin Prevents Cardiomyocyte Hypertrophy, Fibrosis, and Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats
Masayoshi Yamamoto, Tomoko Ishizu, Yoshihiro Seo, et al.
Journal of Cardiac Failure (2017) Vol. 24, Iss. 1, pp. 53-60
Closed Access | Times Cited: 10
Reduced Nhe1 (Na + -H + Exchanger-1) Function Protects ApoE-Deficient Mice From Ang II (Angiotensin II)–Induced Abdominal Aortic Aneurysms
Cong-Lin Liu, Xin Liu, Yunzhe Wang, et al.
Hypertension (2020) Vol. 76, Iss. 1, pp. 87-100
Open Access | Times Cited: 10
Role of Dipeptidyl Peptidase-4 in Atherosclerotic Cardiovascular Disease in Humans and Animals with Chronic Stress
Limei Piao, Yanglong Li, Megumi Narisawa, et al.
International Heart Journal (2021) Vol. 62, Iss. 3, pp. 470-478
Open Access | Times Cited: 9
Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial
Koh Ono, Hiromichi Wada, Noriko Satoh‐Asahara, et al.
American Journal of Cardiovascular Drugs (2019) Vol. 20, Iss. 3, pp. 283-293
Open Access | Times Cited: 9
Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
Liying Mu, Zhuo Wang, Jinmei Ren, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 16, Iss. 1, pp. 49-59
Open Access | Times Cited: 6
The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor
Xiu Feng, Qingwei Gu, Gu Gao, et al.
Annales d Endocrinologie (2020) Vol. 81, Iss. 5, pp. 476-481
Closed Access | Times Cited: 8
The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle
Hongliang Li, Jin Ryeol An, Minju Park, et al.
European Journal of Pharmacology (2022) Vol. 935, pp. 175305-175305
Closed Access | Times Cited: 5
Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction
Jingwei Li, Yundai Chen, Wei‐Ren Chen, et al.
Cardiovascular Diabetology (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 5
IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW
Adnan A. Zainal, Marwan M. Merkhan
Military Medical Science Letters (2022) Vol. 91, Iss. 2, pp. 140-160
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top